Skip to main navigation Skip to search Skip to main content

An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer

  • Joseph R. Habib
  • , Ingmar F. Rompen
  • , Brady A. Campbell
  • , Paul C.M. Andel
  • , Benedict Kinny-Köster
  • , Ryte Damaseviciute
  • , D. Brock Hewitt
  • , Greg D. Sacks
  • , Ammar A. Javed
  • , Marc G. Besselink
  • , Hjalmar C. van Santvoort
  • , Lois A. Daamen
  • , Martin Loos
  • , Jin He
  • , I. Quintus Molenaar
  • , Markus W. Büchler
  • , Christopher L. Wolfgang*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

13 Downloads (Pure)

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) is resected at smaller sizes compared with its biologically distinct counterpart, pancreatic intraepithelial neoplasia (PanIN)-derived PDAC. Thus, experts proposed T1 sub-staging for IPMN-derived PDAC. However, this has never been validated. METHODS: Consecutive upfront surgery patients with IPMN-derived PDAC from 5 international high-volume centers were classified by the proposed T1 sub-staging classification (T1a ≤0.5, T1b >0.5 and ≤1.0, and T1c >1.0 and ≤2.0 cm) using the invasive component size. Kaplan-Meier and log-rank tests were used to compare overall survival (OS). A multivariable Cox regression was used to determine hazard ratios (HRs) with confidence intervals (95% CIs). RESULTS: Among 747 patients, 69 (9.2%), 50 (6.7%), 99 (13.0%), and 531 patients (71.1%), comprised the T1a, T1b, T1c, and T2-4 subgroups, respectively. Increasing T-stage was associated with elevated CA19-9, poorer grade, nodal positivity, R1 margin, and tubular subtype. Median OS for T1a, T1b, T1c, and T2-4 were 159.0 (95% CI = 126.0 to NR), 128.8 (98.3 to NR), 77.6 (48.3 to 108.2), and 31.4 (27.5 to 37.7) months, respectively (P < .001). OS decreased with increasing T-stage for all pairwise comparisons (all P < .05). After risk adjustment, older than age 65, elevated CA19-9, T1b [HR = 2.55 (1.22 to 5.32)], T1c [HR = 3.04 (1.60 to 5.76)], and T2-4 [HR = 3.41 (1.89 to 6.17)] compared with T1a, nodal positivity, R1 margin, and no adjuvant chemotherapy were associated with worse OS. Disease recurrence was more common in T2-4 tumors (56.4%) compared with T1a (18.2%), T1b (23.9%), and T1c (36.1%, P < .001). CONCLUSION: T1 sub-staging of IPMN-derived PDAC is valid and has significant prognostic value. Advancing T1 sub-stage is associated with worse histopathology, survival, and recurrence. T1 sub-staging is recommended for future guidelines.

Original languageEnglish
Pages (from-to)1791-1797
Number of pages7
JournalJournal of the National Cancer Institute
Volume116
Issue number11
DOIs
Publication statusPublished - 1 Nov 2024

Fingerprint

Dive into the research topics of 'An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer'. Together they form a unique fingerprint.

Cite this